Citadel Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$7.66M Buy
442,560
+218,464
+97% +$3.78M ﹤0.01% 1561
2025
Q1
$4.9M Buy
224,096
+111,673
+99% +$2.44M ﹤0.01% 1773
2024
Q4
$3.59M Sell
112,423
-85,710
-43% -$2.74M ﹤0.01% 2064
2024
Q3
$5.71M Buy
198,133
+44,242
+29% +$1.28M ﹤0.01% 1662
2024
Q2
$5.9M Sell
153,891
-1,032,191
-87% -$39.6M ﹤0.01% 1560
2024
Q1
$69.7M Buy
1,186,082
+900,965
+316% +$53M 0.01% 368
2023
Q4
$17.1M Buy
285,117
+270,370
+1,833% +$16.2M ﹤0.01% 923
2023
Q3
$561K Sell
14,747
-513,825
-97% -$19.5M ﹤0.01% 3628
2023
Q2
$48.2M Buy
528,572
+354,512
+204% +$32.3M 0.01% 438
2023
Q1
$11.5M Buy
174,060
+168,791
+3,203% +$11.1M ﹤0.01% 1214
2022
Q4
$272K Sell
5,269
-42,892
-89% -$2.22M ﹤0.01% 4425
2022
Q3
$3.29M Sell
48,161
-149,298
-76% -$10.2M ﹤0.01% 2254
2022
Q2
$8.93M Sell
197,459
-231,793
-54% -$10.5M ﹤0.01% 1363
2022
Q1
$21.8M Sell
429,252
-524,479
-55% -$26.6M ﹤0.01% 856
2021
Q4
$45.1M Sell
953,731
-904,701
-49% -$42.8M 0.01% 523
2021
Q3
$61.3M Buy
1,858,432
+1,505,416
+426% +$49.6M 0.01% 372
2021
Q2
$22.3M Buy
353,016
+300,464
+572% +$19M 0.01% 884
2021
Q1
$2.26M Sell
52,552
-1,384,394
-96% -$59.4M ﹤0.01% 3022
2020
Q4
$82.2M Sell
1,436,946
-765,312
-35% -$43.8M 0.02% 265
2020
Q3
$66.4M Buy
2,202,258
+832,498
+61% +$25.1M 0.02% 288
2020
Q2
$44.7M Buy
1,369,760
+634,920
+86% +$20.7M 0.02% 414
2020
Q1
$19.7M Buy
734,840
+178,480
+32% +$4.78M 0.01% 674
2019
Q4
$17M Buy
+556,360
New +$17M 0.01% 875
2019
Q3
Sell
-641,720
Closed -$16.3M 4647
2019
Q2
$16.3M Sell
641,720
-303,464
-32% -$7.69M 0.01% 912
2019
Q1
$18.4M Buy
945,184
+894,915
+1,780% +$17.5M 0.01% 784
2018
Q4
$663K Sell
50,269
-13,443
-21% -$177K ﹤0.01% 3086
2018
Q3
$1.13M Buy
63,712
+52,445
+465% +$932K ﹤0.01% 2615
2018
Q2
$247K Buy
+11,267
New +$247K ﹤0.01% 3559